Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: A phase I study

Revista Espanola de Quimioterapia

Volumn 20, Issue 1, 2007, Pages 51-60

  Sádaba, Belén ^a,c   Azanza, J R ^a   Quetglas, E G ^a   Campanero, M A ^a   Honorato, J ^a   Coronel, P ^b   Gimeno, M ^b  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Tedec Meiji Farma SA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cefditoren pivoxil; Multiple doses; Pharmacokinetics; PK PD; Tolerance

Indexed keywords

CEFDITOREN PIVOXIL;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; URINALYSIS; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; DIARRHEA; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 34250813732     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Spangler, S.K., Jacobs, M.R., Appelbaum, P.C. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams. J Antimicrob Chemother 1997; 39: 141-148.
2. Wellington, K., Curran, M.P. Cefditoren pivoxil: A review of its use in the treatment of bacterial infections. Drugs 2004; 64: 2597-2618.
3. Li, J.T., Hou, F., Lu, H. et al. Phase I clinical trial of cefditoren pivoxil (ME 1207): Pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 1997; 23: 145-150.
4. Sawchuk, R.J., Mulford, D.J., Mayer, M.D. Unique antibacterial properties of cefditoren. Pharmacokinetics of a new cephalosporin. J Respir Dis 2001; 22(Suppl 8): S43-S51
5. Craig, W.A., Andes, D.R. Parenteral versus oral antibiotic therapy. Med Clin North Am 1995; 79: 497-508.
6. Drusano, G.L., Craig, W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
7. Schentag, J.J., Nix, D.E., Adelman, M.H. Mathematical examination of dual individualization principles (I), relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Ann Pharmacother 1991; 25: 1050-1057.
8. Soriano, F., Granizo, J.J., Fenoll, A. et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: Results from the cefditoren surveillance program. J Chemother 2003; 15: 107-112.
9. Dubois, J., St-Pierre, C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Micr Infec Dis 2000; 37: 187-193.
10. Spangler, S.K., Jacobs, M.R., Appelbaum, P.C. Time-kill studies on susceptibility of nine penicillin-susceptible and penicillin-resistant pneumococci to cefditoren compared with nine other beta-lactams. J Antimicrob Chemother 1997; 39: 141-148.
11. Felmingham, D., Robbins, M.J., Ghosh, G. et al. An in vitro characterization of cefditoren, a new oral cephalosporin. Drug Exp Clin Res 1994; 20: 127-147.
12. Mulford, D., Mayer, M., Witt, G. Effect of age and gender on the pharmacokinetics of cefditoren. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 2000; Abstr. 310.
13. Mulford, D., Mayer, M., Witt, G. Effect of renal impairment on the pharmacokinetics of cefditoren. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 2000; Abstr. 311.
14. Mayer, M., Mulford, D., Witt, G. Pharmacokinetics of cefditoren in blister fluid and plasma. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 2000; Abstr. 656.
15. Mayer, M., Mulford, D., Witt, G. Effect of hepatic impairment on the pharmacokinetics of cefditoren. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 2000; Abstr. 312.
16. Guay, D.R. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001; 23: 1924-1937.
17. Meiact tablets (cefditoren pivoxil). Summary of the Product Characteristics. Available at http://sinaem.agemed.es:83/presentacion/principal. asp (12 Dec 2005, date last accessed).
18. Cars, O. Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-33.
19. Darkes, M.J., Plosker, G.L. Cefditoren pivoxil. Drugs 2002; 62: 319-336.
20. Vogelman, B., Gudmundsson, S., Leggett, J. et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
21. Frimodt-Moller, N., Bentzon, M.W., Thomsen, V.F. Experimental infection with Streptococcus pneumoniae in mice, correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986; 154: 511-517.
22. McKinnon. P.S., Paladino, J.A., Schentag, J.J. Evaluation of AUC24/CMI as a predictor of outcome for advanced generation cephalosporins in serious bacterial infections. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995; Abstr. A58.
23. Sádaba, B., Azanza, J.R., Campanero, M.A., García-Quetglas, E. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect 2004; 10: 990-998.
24. Jones, R.N., Biedenbach, D.J., Johnson, D.M. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Micr Infec Dis 2000; 37: 143-146.
25. García-de-Lomas, J., Lerma, M., Cebrián, L. et al. Comparative susceptibility of E. coli isolates exhibiting different resistance phenotypes to cefditoren, cefminox and other antibiotics. 8th European Congress of Chemotherapy and Infection, Budapest, Hungary 2006; poster.
26. Li, J.T., Hou, F., Lu, H., Li, T.Y., Li, H. Phase I clinical trial of cefditoren pivoxil (MEI207). Tolerance in healthy volunteers. Drugs Exp Clin Res 1997; 23: 131-138.